… can be involved in the pathogenesis of L-dopa-induced dyskinesia in patients with Parkinson’s disease. Project … in Parkinson’s disease and, particularly for L-DOPA-induced dyskinesia. The discovery of compounds able to alter D1-D3 … to obvious experiments in animal models of L-DOPA-induced dyskinesia. If those compounds are not suitable for clinical …

… without increasing or with decreasing the "on" time of dyskinesia and with fewer levodopa doses per day. These … Dyskinesia …

… disease, induces severe involuntary movements termed dyskinesias. The development of these motor dysfunctions has … of SHP-2 expression alleviates levodopa-induced dyskinesias in an experimental model of Parkinson’s disease. … prevents the development of levodopa-induced dyskinesias. Hemi-parkinsonian rats with low levels of …

… to induce a loss of muscle control (levodopa-induced dyskinesia or LID) that almost always besets Parkinson’s … We also found that HE3286 decreased levodopa-induced dyskinesia better than placebo and better than amanatidine, an FDA-approved drug to reduce the dyskinesia side effect. No safety or side effect problems …

… clinically similar to PD, and chronic, late onset, tardive dyskinesia (TD), which is clinically similar to L-dopa induced dyskinesia (LID). Besides demographic and clinical risk … Dyskinesia …

… underlies the development of troubling levodopa-induced dyskinesia that affects many PD patients. One strategy is to … dopamine release and completely abolished the dyskinesia-like symptoms observed in models of PD. These … a promising therapeutic for treatment of levodopa-induced dyskinesia. Hypothesis: Our hypothesis is that NLX-112 …